a:5:{s:8:"template";s:9184:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="text/html; charset=utf-8" http-equiv="content-type"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Roboto+Condensed%3A300%2C300i%2C400%2C400i%2C600%2C600i%2C800%2C800i&amp;subset=latin%2Clatin-ext" id="bulk-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}p.has-drop-cap:not(:focus)::first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}p.has-drop-cap:not(:focus)::after{content:"";display:table;clear:both;padding-top:14px} @font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:300;src:local('Roboto Condensed Light Italic'),local('RobotoCondensed-LightItalic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVg2ZhZI2eCN5jzbjEETS9weq8-19eDpCEoY9Nc.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:400;src:local('Roboto Condensed Italic'),local('RobotoCondensed-Italic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVj2ZhZI2eCN5jzbjEETS9weq8-19eLAQM4.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:300;src:local('Roboto Condensed Light'),local('RobotoCondensed-Light'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVi2ZhZI2eCN5jzbjEETS9weq8-33mZGCoYag.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:400;src:local('Roboto Condensed'),local('RobotoCondensed-Regular'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVl2ZhZI2eCN5jzbjEETS9weq8-19y7CA.ttf) format('truetype')} /*! normalize.css v3.0.3 | MIT License | github.com/necolas/normalize.css */html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}.text-center{text-align:center}ul{margin-top:0;margin-bottom:10px}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-brand{float:left;padding:15px 15px;font-size:18px;line-height:20px;height:50px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}@media (min-width:768px){.navbar-right{float:right!important;margin-right:-15px}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{content:" ";display:table}.container-fluid:after,.container:after,.nav:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}body,html{overflow-x:hidden}body{font-family:'Roboto Condensed',"Helvetica Neue",helvetica,arial,sans-serif;padding:0;color:#404040;font-weight:400;line-height:1.8;font-size:16px;word-wrap:break-word;overflow-x:hidden}a,a:active,a:focus,a:hover{text-decoration:none;color:#0090ff}ul{padding-left:20px}a:active{border-bottom:none}.page-area{padding-top:70px}@media (min-width:768px){.navbar-nav>li>a{padding-top:25px;padding-bottom:25px;transition:all .5s ease-in-out;-moz-transition:all .5s ease-in-out;-webkit-transition:all .5s ease-in-out;-o-transition:all .5s ease-in-out}#site-navigation .container{padding-left:0;padding-right:0}}@media (max-width:767px){.navbar-nav a:focus,.navbar-nav a:hover{color:#fff!important;background-color:#000!important}.menu-container{width:70%;position:absolute;left:0;height:100vh;transform:translate3d(-100%,0,0);overflow-y:auto;overflow-x:auto;background-color:#fff;top:100%}.navbar-brand{padding-right:55px!important}.page-area{left:0;transform:translate3d(0,0,0);transition:transform .5s ease}.navbar-nav{padding:0;margin:0}.navbar-nav a{font-size:14px;padding:12px 10px!important;margin:0!important;line-height:16px!important;float:left!important;margin:0!important;width:100%;text-transform:none!important;word-wrap:break-word;white-space:normal!important}.navbar-nav li{padding:0!important;margin:0!important}}#site-navigation{min-height:70px}.navbar-nav>li>a{border-bottom:0;text-transform:uppercase}.site-title{margin:0;padding:0;font-size:22px;line-height:28px}p.site-description{font-size:13px;line-height:18px;margin:0;-webkit-transition:all .5s ease;transition:all .5s ease}.site-branding-logo{float:left}.site-branding-logo a{border:none;z-index:9999;position:relative}.navbar-brand{padding:10px 15px;height:auto;z-index:99999;position:relative;z-index:1}.navbar{margin-bottom:0}.main-menu{position:relative}.navbar-fixed-top{position:absolute}#site-navigation{background-color:#fff;-webkit-box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);border:none}#site-navigation,nav a{-webkit-transition:all .3s ease;transition:all .3s ease;color:#000}.footer-credits{border-top:1px solid #ccc;padding:15px;clear:both;margin-top:20px;background-color:#fff}</style>
 </head>
<body class="wp-custom-logo" id="blog">
<div class="main-menu">
<nav class="navbar navbar-default navbar-fixed-top" id="site-navigation">
<div class="container">
<div class="navbar-header">
<div class="site-header">
<div class="site-branding-logo">
<a class="custom-logo-link" href="#" itemprop="url" rel="home"></a> </div>
<div class="site-branding-text navbar-brand">
<p class="site-title"><a href="#" rel="home">{{ keyword }}</a></p>
<p class="site-description">
{{ keyword }}</p>
</div>
</div>
</div>
<div class="menu-container"><ul class="nav navbar-nav navbar-right" id="menu-menu-1"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-72 dropdown" id="menu-item-72"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="Projects">Projects</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73 dropdown" id="menu-item-73"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="About">About</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-74" id="menu-item-74"><a href="#" title="Contacts">Contacts</a></li>
</ul></div> </div>
</nav>
</div>
<div class="page-area">	
{{ text }}
<br>
<br>
{{ links }}
</div>
<footer class="footer-credits container-fluid row" id="colophon">
<div class="container">
<p class="footer-credits-text text-center">{{ keyword }} 2020</p>
</div>
</footer>
</body>
</html>";s:4:"text";s:11446:"<br>Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund. Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The acquisition gives Roche full rights to Inflazome’s entire portfolio. The deal gives Roche full rights to Inflazome’s entire portfolio of clinical and preclinical small molecule NLRP3 inhibitors. Inflazome was founded in 2016 by Cooper, then a medical researcher at the University of Queensland in Australia, and Luke O’Neill, a medical researcher at Trinity College Dublin. Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). Inzomelid is the most advanced asset covered by … 'It was pure fluke she wore them' - part-time Irish jeweller designer experiences 'Kate Effect' after Duchess wears pendant, Ryanair to close Cork and Shannon bases for the winter, Distributor balks at brand's White House links, Aer Lingus has paid €710m in dividends since buyout by IAG, Judge refuses examinership application by fashion chain New Look. Jordan will help you find what you are looking for. Inflazome is headquartered in Dublin, Ireland. Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome. Don't miss your daily pharmaphorum news.                                             Sections, Inflazome co-founders Luke O’Neill, left, and Matt Cooper, Ellie Donnelly                                        Twitter Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases. The rights of trade mark owners are acknowledged. The acquisition gives Roche full access to Inflazome’s portfolio of orally available NLRP3 inhibitors which the company intended to continue to develop for a range of indications. Along with the €380m payment, shareholders are eligible to receive additional milestone payments. <br> <br>Somalix meanwhile is intended for the treatment of conditions that affect the rest of the body, such as cardiovascular disease, gout, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and osteoarthritis. Inflazome  <br> <br>Matt Cooper, CEO of Inflazome, said: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need. <br> <br>With Inflazome now part of the Roche organisation, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”. The Swiss pharma giant is paying €380 million (around $450 million) upfront for Dublin-based Inflazome, getting rights to a portfolio of oral NLRP3-targeting drugs including two candidates at the clinical testing stage, and has also pledged undisclosed milestone payments. The company, which was founded in 2016, has raised €55m in two rounds of funding. pharmaphorum media limited. Jecure began operations in 2015 with seed financing from founding investor Versant Ventures, raising anther $20 million in a Series A in 2017 before being acquired by the Swiss group. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.  Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of … In one of the largest deals in Irish biotech history, Roche has acquired Inflazome for €380 million. The company’s research focuses on developing drugs to inhibit the NLRP3 danger sensor in immune cells called inflammasomes.These cells are understood to be involved in a range of chronic inflammatory conditions including Parkinson’s, Alzheimer’s, inflammatory bowel disease, cardiovascular disease and arthritis. When it bought Jecure in 2018, claiming access to a portfolio of preclinical NLRP3 inhibitor candidates, Roche highlighted the potential of the class in NASH, a disease with no approved therapies that some believe could become a multibillion-dollar revenue opportunity. The company’s lead molecules have successfully completed Phase 1 clinical trials, as well as several high potential earlier-stage programs. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need. Author: Elaine Burridge, Freelance Journalist, Advertising Opportunities Print, Digital & Content Solutions. Inflazome’s shareholders received an upfront payment of €380 million and are eligible to receive additional milestone payments. Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up Jecure Therapeutics of … With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”, Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)--Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up Jecure Therapeutics of the US for an undisclosed sum. Dr Jeremy Skillington | VP Business Development <br> <br>Inzomelid can cross the blood brain barrier and so is being developed for diseases of the central nervous system that have an inflammatory component, such as Parkinson’s, Alzheimer’s and motor neurone disease. It has been designed not to penetrate the CNS. Inflazome was founded in 2016 by medical researchers Prof Matt Cooper of University of Queensland, Australia and Prof Luke O’Neill of Trinity College Dublin.  <br>THE Dublin-headquartered Inflazome has been bought by pharma group Roche, in a deal that will see shareholders receive €380m upfront. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes. The biotech thinks they can reduce the damage caused by chronic, uncontrolled inflammation, without dampening down other, beneficial inflammatory responses involved in fighting off infection and healing damaged tissue. BioSpace. We keep you posted - Subscribe to the CHEManager International newsletter here! Still haven't found what you're looking for? All Rights Reserved. Research and Markets partners with charity: water. <br> <br>E: j.skillington@inflazome.com, UK & International | Ciara Martin/Tim Stamper Menu SUBSCRIBE free here. Website and content copyright © 2009-, pharmaphorum media limited or its licensors; THE Dublin-headquartered Inflazome has been bought by pharma group Roche, in a deal that will see shareholders receive €380m upfront. 05.10.2020 Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases. all rights reserved. Headquartered in Dublin, Inflazome regards itself as a leader in the development of inflammasome inhibitors. We will help you find what you are looking for. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. According to the company, these drugs are useful in the treatment of a wide range of disorders, from Parkinson's, Alzheimer's and motor neurone disease to asthma, inflammatory bowel disease and arthritis. It is developing drugs that block harmful inflammation. T: +44 20 37271000, Ireland & International | Jonathan Neilan/Patrick Berkery These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. Irish biotech company Inflazome has been acquired by Swiss multinational healthcare company Roche for €380m - one of the largest deals in Irish biotech history. <br> Inflazome’s shareholders received an upfront payment of €380 million and are eligible to receive additional milestone payments. Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome. Acquisition of Inflazome gives Roche full rights to the Inflazome portfolio. On the Roche deal, Dr Cooper noted the Swiss group’s commitment to addressing a wide range of medical conditions and said: “We are delighted to close this deal with Roche. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Inflazome announces acquisition by Roche. Inflazome … Earlier this year, Inflazome reported initial clinical results showing that a patient with CAPS showed signs of improvement in symptoms after inzomelid treatment, prompting it to plan a phase 2 trial. These are used to treat a large number of diseases ranging from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and the liver disease nonalcoholic steatohepatitis (NASH). Inflazome’s portfolio currently includes two drugs that have already successfully completed phase 1 clinical trials. Inflazome has today announced that it has closed a share purchase agreement with Roche. Speak to our Custom Research Team. HVAC (Heating, Ventilation, & Air Conditioning). Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years … These are used to treat a large number of diseases ranging from Parkinson’s and …  -   Swiss drugmaker Roche has acquired Irish biotech Inflazome for €380 million, said to be one of the largest deals in Irish biotech history. Inflazome meanwhile emerged onto the scene in 2016, coming out of stealth mode with a $17 million Series A financing backed by Novartis’ venture capital arm, and following that in the same year with a $46 million second round. <br>";s:7:"keyword";s:15:"inflazome roche";s:5:"links";s:3297:"<a href='http://newdestinychurchpc.com/blog/article.php?tag=michael-verhoeven-6bb478'>Michael Verhoeven</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=Rockstar-New-England-6bb478'>Rockstar New England</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=Iv%C3%A1n-Marcone-6bb478'>Iván Marcone</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=give-me-love-%28give-me-peace-on-earth-meaning%29-6bb478'>Give Me Love (give Me Peace On Earth Meaning)</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=point-break-online-6bb478'>Point Break Online</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=shepparton-hotel-6bb478'>Shepparton Hotel</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=by-the-end-of-the-night-country-song-6bb478'>By The End Of The Night Country Song</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=netflix-streaming-movies-6bb478'>Netflix Streaming Movies</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=matt-duchene-hockeydb-6bb478'>Matt Duchene Hockeydb</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=Chinese-Coffee-6bb478'>Chinese Coffee</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=out-of-my-mind-pdf-6bb478'>Out Of My Mind Pdf</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=johnson-and-johnson-interview-questions-6bb478'>Johnson And Johnson Interview Questions</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=a-bronx-tale-online-6bb478'>A Bronx Tale Online</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=minimum-necessary-income-to-sponsor-spouse-in-canada-6bb478'>Minimum Necessary Income To Sponsor Spouse In Canada</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=Germany-Japan-relations-6bb478'>Germany Japan Relations</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=terminus-pantheon-6bb478'>Terminus Pantheon</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=tommy-emmanuel-fuel-lesson-6bb478'>Tommy Emmanuel Fuel Lesson</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=sacramento-kings-colors-6bb478'>Sacramento Kings Colors</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=Mike-Tyson-house-Arizona-6bb478'>Mike Tyson House Arizona</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=lomachenko-vs-lopez-how-to-watch-6bb478'>Lomachenko Vs Lopez How To Watch</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=alex-gorsky-personality-6bb478'>Alex Gorsky Personality</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=first-round-capital-careers-6bb478'>First Round Capital Careers</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=unknown-2-6bb478'>Unknown 2</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=eddie-brock-toxin-6bb478'>Eddie Brock Toxin</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=carey-price-children-6bb478'>Carey Price Children</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=adelphi-university-6bb478'>Adelphi University</a>,
<a href='http://newdestinychurchpc.com/blog/article.php?tag=marian-gaborik-retire-6bb478'>Marian Gaborik Retire</a>,
";s:7:"expired";i:-1;}